PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19271688-0 2008 Quantitative analysis of expression level of BCL2 and BAX genes in Hep-2 and HL-60 cells after treatment with etoposide. Etoposide 110-119 BCL2 apoptosis regulator Homo sapiens 45-49 20189983-9 2010 Bcl-2- and Mcl-1-mediated protection from apoptosis induced by staurosporine or etoposide was enhanced in cells expressing InsP(3)R, demonstrating that their interactions with InsP(3)R enable Bcl-2 and Mcl-1 to be fully efficacious anti-apoptotic mediators. Etoposide 80-89 BCL2 apoptosis regulator Homo sapiens 0-5 19777212-7 2009 Camptothecin and etoposide caused an increase of protein expression of several cell-cycle regulators and induced the cleavage of Bcl-2 family of proteins. Etoposide 17-26 BCL2 apoptosis regulator Homo sapiens 129-134 19410573-8 2009 Namely, bortezomib abrogated both etoposide-induced NF-kappaB activation and etoposide-induced bcl-2 up-regulation. Etoposide 77-86 BCL2 apoptosis regulator Homo sapiens 95-100 18927073-4 2008 Cells stably overexpressing Bcl-2/Bcl-x(L) or stably depleted of Apaf-1 were equally resistant to apoptosis induced by the DNA-damaging anticancer drug etoposide as determined by phosphatidylserine externalization and caspase activation. Etoposide 152-161 BCL2 apoptosis regulator Homo sapiens 28-33 17785460-6 2007 The induction of Bcl-2 inhibited apoptosis induced by serum starvation or etoposide, and PKCepsilon activation attenuated etoposide-induced caspase-3 cleavage. Etoposide 74-83 BCL2 apoptosis regulator Homo sapiens 17-22 18939359-0 2008 [Changes in etoposide-induced apoptosis of HeLa tumor cells transfected with antisense oligonucleotide for BCL-2 mRNA]. Etoposide 12-21 BCL2 apoptosis regulator Homo sapiens 107-112 18939359-13 2008 The use of the anti-BCL-2 oligonucleotide in combination with etoposide results in significant deacrease of proliferation in cell cultures and this phenomenon is a result of synergy between used chemotherapy and gene therapy. Etoposide 62-71 BCL2 apoptosis regulator Homo sapiens 20-25 17574594-5 2008 MATERIALS AND METHODS: Bcl-2 expression was analyzed in the HB cell lines HUH6 and HepT1 as well as in the HCC cell line HepG2 before and after treatment with cisplatin, doxorubicin, taxol, and etoposid. Etoposide 194-202 BCL2 apoptosis regulator Homo sapiens 23-28 17785460-6 2007 The induction of Bcl-2 inhibited apoptosis induced by serum starvation or etoposide, and PKCepsilon activation attenuated etoposide-induced caspase-3 cleavage. Etoposide 122-131 BCL2 apoptosis regulator Homo sapiens 17-22 17544220-8 2007 Etoposide decreased the expression of Bcl-2, which was reversed by LPA. Etoposide 0-9 BCL2 apoptosis regulator Homo sapiens 38-43 17544840-4 2007 Intracellular galectin-3 in particular, which contains the NWGR anti-death motif of the Bcl-2 family, inhibits cell apoptosis induced by chemotherapeutic agent such as cisplatin and etoposide in some types of cancer cells. Etoposide 182-191 BCL2 apoptosis regulator Homo sapiens 88-93 17384250-0 2006 Alterations in mRNA expression of apoptosis-related genes BCL2, BAX, FAS, caspase-3, and the novel member BCL2L12 after treatment of human leukemic cell line HL60 with the antineoplastic agent etoposide. Etoposide 193-202 BCL2 apoptosis regulator Homo sapiens 58-62 17384250-3 2006 The aim of the present research approach to investigate the expression of the apoptosis-related genes BCL2 (Bcl-2), FAS, Caspase-3, BAX and the new member BCL2L12, cloned by our group, along with treatment of HL-60 leukemia cells with etoposide. Etoposide 235-244 BCL2 apoptosis regulator Homo sapiens 102-106 16682503-5 2006 Lithium and OA abrogated ceramide- and etoposide-induced Bcl-2 dephosphorylation at serine 70. Etoposide 39-48 BCL2 apoptosis regulator Homo sapiens 57-62 16895478-0 2006 Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS. Etoposide 40-49 BCL2 apoptosis regulator Homo sapiens 124-128 15817479-0 2005 Bcl-2 rescues ceramide- and etoposide-induced mitochondrial apoptosis through blockage of caspase-2 activation. Etoposide 28-37 BCL2 apoptosis regulator Homo sapiens 0-5 16297990-13 2006 The ratio Bcl-2/Bax was reduced in parental or mock-transfected PC-3 cells after treatment with etoposide. Etoposide 96-105 BCL2 apoptosis regulator Homo sapiens 10-15 15817479-12 2005 Taken together, ceramide and etoposide induced mitochondria-mediated apoptosis by initiating caspase-2 activation, which was, at least in part, regulated by Bcl-2. Etoposide 29-38 BCL2 apoptosis regulator Homo sapiens 157-162 15817479-6 2005 Overexpression of Bcl-2 prevented ceramide- and etoposide-induced caspase-2 activation and mitochondrial apoptosis. Etoposide 48-57 BCL2 apoptosis regulator Homo sapiens 18-23 15817479-10 2005 Further studies showed that Bcl-2 was dephosphorylated at serine 70 after ceramide and etoposide treatment. Etoposide 87-96 BCL2 apoptosis regulator Homo sapiens 28-33 15674333-3 2005 Here we show that three representative apoptotic stimuli, that is, serum starvation, a mitochondrial toxin, and a DNA-damaging agent (etoposide), rapidly induce several distinct classes of prosurvival molecules, in particular, Bcl-2/Bcl-X(L) and superoxide dismutase (SOD; including both MnSOD and Cu/ZnSOD). Etoposide 134-143 BCL2 apoptosis regulator Homo sapiens 227-232 15143129-5 2004 This is in contrast to chemotherapeutic agents such as etoposide, actinomycin D, and ultraviolet irradiation, whereby overexpression of Bcl-2 confers resistance against apoptosis. Etoposide 55-64 BCL2 apoptosis regulator Homo sapiens 136-141 15829155-0 2005 Insulin-like growth factor-I decreased etoposide-induced apoptosis in glioma cells by increasing bcl-2 expression and decreasing CPP32 activity. Etoposide 39-48 BCL2 apoptosis regulator Homo sapiens 97-102 15829155-11 2005 IGF-I prevented etoposide-induced apoptosis by increasing the expression of bcl-2 and decreasing the activity of CPP32. Etoposide 16-25 BCL2 apoptosis regulator Homo sapiens 76-81 15829155-13 2005 CONCLUSIONS: IGF-I decreased etoposide-induced apoptosis in glioma cells by increasing the expression of bcl-2 and decreasing the activity of CPP32. Etoposide 29-38 BCL2 apoptosis regulator Homo sapiens 105-110 15031723-2 2004 The aim of this study was to investigate if downregulation of bcl-2 or xIAP by RNA interference (RNAi) would sensitize MCF-7 cells to etoposide and doxorubicin. Etoposide 134-143 BCL2 apoptosis regulator Homo sapiens 62-67 15175350-7 2004 Conversely, interference with Bcl-2 function by co-administration of the small molecule Bcl-2 inhibitor HA14-1 or down-regulation of Bcl-2 expression by small interfering RNA or antisense strategies significantly increased mitochondrial dysfunction and apoptosis induced by imatinib mesylate and the topoisomerase inhibitor VP-16 in LAMA-R cells. Etoposide 324-329 BCL2 apoptosis regulator Homo sapiens 30-35 15031723-6 2004 Therefore, downregulation of bcl-2 or xIAP by RNAi enhances the effects of etoposide and doxorubicin. Etoposide 75-84 BCL2 apoptosis regulator Homo sapiens 29-34 14575542-7 2003 In conclusion, the combination of Z-LLL-CHO and VP16 enhanced their individual cytotoxic effect by inducing apoptosis, in which increase of S + G2/M fraction in cell cycle as well as the enhanced cleavage of Bcl-2 are the possible mechanism of the additive effect on leukemic cells by Z-LLL-CHO and VP16. Etoposide 48-52 BCL2 apoptosis regulator Homo sapiens 208-213 14499628-0 2003 Bcl-2 prevents abnormal mitochondrial proliferation during etoposide-induced apoptosis. Etoposide 59-68 BCL2 apoptosis regulator Homo sapiens 0-5 12566077-7 2003 In comparison, Bcl-2 overexpression drastically reduced apoptotic DNA fragmentation by etoposide, acting via topoisomerase II-mediated DNA damage, but had no effect on apoptotic DNA fragmentation by helenalin A, which reacts with proteins but not DNA. Etoposide 87-96 BCL2 apoptosis regulator Homo sapiens 15-20 12536201-8 2003 Combined RNAi for c-raf and bcl-2 induced apoptosis in HL-60, U937, and THP-1 cells and increased chemosensitivity to etoposide and daunorubicin. Etoposide 118-127 BCL2 apoptosis regulator Homo sapiens 28-33 12533044-4 2002 JM-1, SUP-B 15 and RS4 leukemic cell lines cleaved Bcl-2 to its 23 kDa form when exposed to the chemotherapeutic agents 1-beta-D-arabinofuranosyl-cytosine (Ara-C) or etoposide (VP-16). Etoposide 166-175 BCL2 apoptosis regulator Homo sapiens 51-56 12520735-1 2002 BACKGROUND & OBJECTIVE: The previous study has identified two novel antisense oligonucleotides (AS-ODN) of new target point in the translation initiation and the coding region of bcl-2 mRNA that could increase the sensitivity of HL-60 and K562 cells lines to etoposide, daunorubicin, and araninosyl cytosine (Ara-C). Etoposide 263-272 BCL2 apoptosis regulator Homo sapiens 183-188 12063570-9 2002 Further studies in this area are warranted as the roles of p21WAF1, Bax/Bcl-2 and NF-kappaB may be important molecular events in mediating the antiproliferative and apoptosis inducing effect of etoposide in combination with ciprofloxacin in HRPC cells. Etoposide 194-203 BCL2 apoptosis regulator Homo sapiens 72-77 11815602-0 2002 Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposide-induced apoptosis. Etoposide 140-149 BCL2 apoptosis regulator Homo sapiens 74-79 11861801-5 2002 The overexpression of Bcl-2 gene prevented FTY720- and etoposide-mediated apoptosis, but not Fas-mediated apoptosis. Etoposide 55-64 BCL2 apoptosis regulator Homo sapiens 22-27 11402324-7 2001 We have shown that the high levels of Bcl-2 expression in FV-P-induced erythroleukemic cells inhibited apoptosis induced by etoposide, low serum and p53 expression. Etoposide 124-133 BCL2 apoptosis regulator Homo sapiens 38-43 11571709-3 2001 METHODS AND RESULTS: We report an accurate method for quantitative detection of the bcl-2/IgH translocation marker of follicular lymphoma in a series of patients in various stages of remission and relapse who had been treated with a combination of ifosfamide, mitoxantrone, and etoposide (MINE) chemotherapy and monoclonal anti-CD20 antibody (Rituximab). Etoposide 278-287 BCL2 apoptosis regulator Homo sapiens 84-89 11484935-2 2001 We found that four anticancer agents: etoposide, doxorubicin, bleomycin and paclitaxel induced apoptosis in human umbilical vein endothelial cells (HUVECs) (as judged by DNA fragmentation) with a time- and concentration-dependent decrease in bcl-2 protein but without the involvement of p53. Etoposide 38-47 BCL2 apoptosis regulator Homo sapiens 242-247 11402324-8 2001 Similarly, ectopic Bcl-2 expression within these cells also provided protection from apoptosis induced by etoposide and growth in low serum. Etoposide 106-115 BCL2 apoptosis regulator Homo sapiens 19-24 10850456-9 2000 Tumor cells overexpressing Bcl-2 or Bcl-xL become resistant to apoptosis induced by the chemotherapeutic drug etoposide. Etoposide 110-119 BCL2 apoptosis regulator Homo sapiens 27-32 11029754-10 2000 Finally, Bcl-2 overexpression inhibited etoposide-induced calpain activation, Bax cleavage, cytochrome c release, and apoptosis. Etoposide 40-49 BCL2 apoptosis regulator Homo sapiens 9-14 11042671-0 2000 Ordering of ceramide formation, caspase activation, and Bax/Bcl-2 expression during etoposide-induced apoptosis in C6 glioma cells. Etoposide 84-93 BCL2 apoptosis regulator Homo sapiens 60-65 11042671-4 2000 In addition, exposure of cells to etoposide resulted in decreased expression of Bcl-2 with reciprocal increase in Bax protein. Etoposide 34-43 BCL2 apoptosis regulator Homo sapiens 80-85 11042671-6 2000 Reduced glutathione or N-acetylcysteine, which could reduce ceramide formation by inhibiting sphingomyelinase activity, prevented C6 cells from etoposide-induced apoptosis through blockage of caspase-3 activation and change of the Bax/Bcl-2 ratio. Etoposide 144-153 BCL2 apoptosis regulator Homo sapiens 235-240 10930016-11 2000 Furthermore, low concentrations of etoposide also induced apoptosis in the T-98G/p53 cells by enhancing the expression of transfected wild-type p53, decreasing the expression of bcl-2, and activating CPP32 activity. Etoposide 35-44 BCL2 apoptosis regulator Homo sapiens 178-183 10930016-14 2000 CONCLUSIONS: These findings indicate that wild-type p53, CPP32, and bcl-2 may mediate apoptosis induced by etoposide. Etoposide 107-116 BCL2 apoptosis regulator Homo sapiens 68-73 11279616-6 2001 Over-expression of bcl-2 in cx43-transfected cells partially confers the resistance to apoptosis induced by etoposide, suggesting that the cx43-mediated apoptosis to chemotherapeutic agents is regulated in part through the down-regulation of bcl-2 expression. Etoposide 108-117 BCL2 apoptosis regulator Homo sapiens 19-24 11040047-7 2000 When treated with an anticancer drug (etoposide or cisplatin) or the kinase inhibitor staurosporin, the cells containing a high G(1) population and a high Bcl-2 protein level were much more resistant to the induced apoptosis than the cells containing a high S phase population and a low Bcl-2 protein level. Etoposide 38-47 BCL2 apoptosis regulator Homo sapiens 155-160 11040047-7 2000 When treated with an anticancer drug (etoposide or cisplatin) or the kinase inhibitor staurosporin, the cells containing a high G(1) population and a high Bcl-2 protein level were much more resistant to the induced apoptosis than the cells containing a high S phase population and a low Bcl-2 protein level. Etoposide 38-47 BCL2 apoptosis regulator Homo sapiens 287-292 11042671-9 2000 Taken together, these results suggest that ceramide may function as a mediator of etoposide-induced apoptosis of C6 glioma cells, which induces increase in the Bax/Bcl-2 ratio followed by release of cytochrome c leading to caspases-9 and -3 activation. Etoposide 82-91 BCL2 apoptosis regulator Homo sapiens 164-169 10318846-5 1999 Both effector caspase processing and cytochrome c release were inhibited in the resistant variant cells as well as in Bcl-2 transfectants, suggesting that, in Jurkat cells, the apoptosis signaling pathways activated by CD95, etoposide, and gamma-radiation are under common mitochondrial control. Etoposide 225-234 BCL2 apoptosis regulator Homo sapiens 118-123 10428509-11 1999 Etoposide induced a caspase-dependent cleavage of Bcl-2, while actin remained intact. Etoposide 0-9 BCL2 apoptosis regulator Homo sapiens 50-55 10321832-7 1999 However, ECM prevented p21 and Bcl-2 down-regulation induced by taxol or etoposide. Etoposide 73-82 BCL2 apoptosis regulator Homo sapiens 31-36 10839193-0 2000 Differential responses of Bcl-2 family genes to etoposide in chronic myeloid leukemia K562 cells. Etoposide 48-57 BCL2 apoptosis regulator Homo sapiens 26-31 10713725-7 2000 High level overexpression of the anti-apoptotic protein Bcl-2 prevented Bax redistribution to the mitochondria, caspase activation and apoptosis following exposure to staurosporine or etoposide. Etoposide 184-193 BCL2 apoptosis regulator Homo sapiens 56-61 10424444-4 1999 Analysis of cell survival in etoposide-treated cultures indicated that IL-15 was also more potent than IL-2 as a survival factor for CD56+ cells by virtue of its greater ability to up-regulate bcl-2 expression. Etoposide 29-38 BCL2 apoptosis regulator Homo sapiens 193-198 10189371-6 1999 EM showed that cells overexpressing Bcl-2 displayed near-normal morphology and viability in response to vincristine or etoposide. Etoposide 119-128 BCL2 apoptosis regulator Homo sapiens 36-41 10374876-4 1999 Etoposide treatment of these cells triggered a time-dependent activation of type II and type III caspases and cleavage of Bcl-2 yielding a 23 kDa cleavage fragment. Etoposide 0-9 BCL2 apoptosis regulator Homo sapiens 122-127 10374876-7 1999 While evidence for cleavage of Bcl-2 in several subcellular compartments of etoposide-treated cells was obtained, this cleavage was detected predominantly in the mitochondrial fraction, thus providing further support for the central role of mitochondria in apoptosis. Etoposide 76-85 BCL2 apoptosis regulator Homo sapiens 31-36 10374876-8 1999 Caspase-mediated cleavage following etoposide treatment of these myeloid leukemic cells may represent a means for the attenuation of Bcl-2 function upon apoptosis induction. Etoposide 36-45 BCL2 apoptosis regulator Homo sapiens 133-138 10194469-7 1999 Bcl-2 overexpression abrogated the Cer response to etoposide and IR and reduced CD95-induced Cer accumulation. Etoposide 51-60 BCL2 apoptosis regulator Homo sapiens 0-5 10381626-2 1999 Exposure of undifferentiated U937 cells to 50 microM etoposide for 6 h, that triggers apoptosis in 80% cells, activates procaspase-2L, -3 and -8, induces the mitochondrial release of cytochrome c and decreases Mcl-1 expression without modifying Bcl-2, Bcl-xL and Bax protein levels. Etoposide 53-62 BCL2 apoptosis regulator Homo sapiens 245-250 10367743-3 1999 PURPOSE: The purpose of this study was to identify the point at which Bcl-2 interrupts the apoptotic cascade initiated following exposure of human tumor cells to etoposide. Etoposide 162-171 BCL2 apoptosis regulator Homo sapiens 70-75 10367743-10 1999 However, inhibition of etoposide-induced apoptosis by Bcl-2 resulted in the accumulation of giant, multinucleated cells that eventually lost the ability to exclude trypan blue without apoptotic morphology or DNA degradation. Etoposide 23-32 BCL2 apoptosis regulator Homo sapiens 54-59 9792147-2 1998 In the present study, the interactions between the bcl-2 antisense oligodeoxynucleotide 2009 and the chemotherapeutic agents etoposide, doxorubicin and cisplatin were investigated on small-cell lung cancer cell lines to search for synergistic combinations. Etoposide 125-134 BCL2 apoptosis regulator Homo sapiens 51-56 9840719-0 1998 Bcl-2 expression correlates with apoptosis induction but not loss of clonogenic survival in small cell lung cancer cell lines treated with etoposide. Etoposide 139-148 BCL2 apoptosis regulator Homo sapiens 0-5 9840719-1 1998 The influence of bcl-2 oncogene expression on etoposide-induced apoptosis and clonogenic survival was investigated in five small cell lung cancer (SCLC) cell lines, three of which were bcl-2-expressing and two of which were non-bcl-2-expressing. Etoposide 46-55 BCL2 apoptosis regulator Homo sapiens 17-22 9840719-3 1998 When bcl-2-expressing cells were incubated in cystine/ methionine-free (CMF) medium, etoposide-induced apoptosis was restored to levels comparable to those seen in non-bcl-2-expressing lines. Etoposide 85-94 BCL2 apoptosis regulator Homo sapiens 5-10 9840719-3 1998 When bcl-2-expressing cells were incubated in cystine/ methionine-free (CMF) medium, etoposide-induced apoptosis was restored to levels comparable to those seen in non-bcl-2-expressing lines. Etoposide 85-94 BCL2 apoptosis regulator Homo sapiens 168-173 9840719-5 1998 In addition, treatment of the two bcl-2-expressing cell lines with etoposide in CMF medium did not modify their clonogenic survival curves compared to treatment in regular medium. Etoposide 67-76 BCL2 apoptosis regulator Homo sapiens 34-39 9840719-6 1998 These results are consistent with the idea that bcl-2 expression modulates etoposide-induced apoptosis but not clonogenic survival. Etoposide 75-84 BCL2 apoptosis regulator Homo sapiens 48-53 9699642-1 1998 Taxol, 1-beta-D-arabinofuranosylcytosine (ara-C), and etoposide induce apoptosis in HL-60 cells that is blocked by overexpression of Bcl-2 or Bcl-xL.A 60-amino acid "loop" domain of Bcl-2 and Bcl-xL that contains phosphorylation sites is known to negatively regulate their antiapoptotic function. Etoposide 54-63 BCL2 apoptosis regulator Homo sapiens 133-138 9699642-1 1998 Taxol, 1-beta-D-arabinofuranosylcytosine (ara-C), and etoposide induce apoptosis in HL-60 cells that is blocked by overexpression of Bcl-2 or Bcl-xL.A 60-amino acid "loop" domain of Bcl-2 and Bcl-xL that contains phosphorylation sites is known to negatively regulate their antiapoptotic function. Etoposide 54-63 BCL2 apoptosis regulator Homo sapiens 182-187 9713486-10 1998 Increased apoptotic responses were generally observed in cell lines that were sensitive to etoposide and this correlated with low ratios of Bcl-2/Bax protein. Etoposide 91-100 BCL2 apoptosis regulator Homo sapiens 140-145 9671409-5 1998 This effect of etoposide is not observed in K562 cells and bcl-2-transfected U937 cells which are less sensitive to drug-induced apoptosis. Etoposide 15-24 BCL2 apoptosis regulator Homo sapiens 59-64 8781438-0 1996 Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. Etoposide 94-103 BCL2 apoptosis regulator Homo sapiens 26-31 9494534-9 1997 Expression of bcl-2 family members (bax, bcl-x) was modulated by fotemustine, etoposide and cisplatin. Etoposide 78-87 BCL2 apoptosis regulator Homo sapiens 14-19 8840993-12 1996 High Bcl-2 and Bcl-xL levels in these cells also inhibited Yama protease activity, PARP degradation, and apoptosis due to clinically relevant concentrations of etoposide and mitoxantrone. Etoposide 160-169 BCL2 apoptosis regulator Homo sapiens 5-10 9671409-6 1998 Nuclear run-on experiments demonstrate that etoposide increases CASP gene transcription in U937 cells, an effect that is prevented by Bcl-2 overexpression. Etoposide 44-53 BCL2 apoptosis regulator Homo sapiens 134-139 9554589-3 1998 Stable expression of Bcl-2 in the human epithelial tumor (HeLa) cell line results in inhibition of apoptosis following exposure to the topoisomerase II poison, etoposide. Etoposide 160-169 BCL2 apoptosis regulator Homo sapiens 21-26 9554589-5 1998 PURPOSE: The purpose of this study was to further investigate the role of Bcl-2 in human epithelial tumor cell drug resistance using 5-fluoro-2"-deoxyuridine, staurosporine, and doxorubicin, in addition to etoposide. Etoposide 206-215 BCL2 apoptosis regulator Homo sapiens 74-79 9554589-8 1998 RESULTS: Despite profound inhibition to loss of plasma membrane integrity for all agents tested, Bcl-2 was only able to significantly increase clonogenic survival following exposure to 5-fluoro-2"-deoxyuridine and staurosporine, but not following exposure to etoposide or doxorubicin. Etoposide 259-268 BCL2 apoptosis regulator Homo sapiens 97-102 9852210-0 1998 Bcl-2- and CrmA-inhibitable dephosphorylation and cleavage of retinoblastoma protein during etoposide-induced apoptosis. Etoposide 92-101 BCL2 apoptosis regulator Homo sapiens 0-5 9852210-5 1998 Here, we report that expression of the Bcl-2 oncoprotein, an inhibitor of caspases (interleukin 1 -converting enzyme-like proteases), blocked RB dephosphorylation, RB cleavage and apoptosis in etoposide-treated human Jurkat T cells. Etoposide 193-202 BCL2 apoptosis regulator Homo sapiens 39-44 9201973-3 1997 In the present study, Bcl-2 suppressed cell death of N18TG neuroglioma cells caused by various apoptotic stresses, including etoposide, staurosporine, anisomycin, and ultraviolet irradiation. Etoposide 125-134 BCL2 apoptosis regulator Homo sapiens 22-27 9201973-5 1997 Bcl-2 also prevented the etoposide-induced stimulation of MEKK1. Etoposide 25-34 BCL2 apoptosis regulator Homo sapiens 0-5 8943258-1 1996 Bax, a member of the Bcl-2 family of proteins, has been shown to accelerate apoptosis induced by growth factor withdrawal, gamma-irradiation, and the chemotherapeutic agent, etoposide. Etoposide 174-183 BCL2 apoptosis regulator Homo sapiens 21-26 8781438-3 1996 Doxorubicin, etoposide, and hydrogen peroxide consistently induced a concentration- and time-dependent upregulation of BCL-2 expression in all myeloma target cell types assayed by flow cytometry and Western blot analysis. Etoposide 13-22 BCL2 apoptosis regulator Homo sapiens 119-124 8752171-0 1996 Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. Etoposide 31-40 BCL2 apoptosis regulator Homo sapiens 79-84 8781438-9 1996 In addition, BCL-2-transfected IM-9 cells, with enhanced expression of BCL-2 which was comparable to that achieved by initial exposure to doxorubicin, were resistant to doxorubicin and etoposide cytotoxicity. Etoposide 185-194 BCL2 apoptosis regulator Homo sapiens 13-18 8752171-1 1996 The Bcl-2 oncoprotein, which is expressed in a variety of human malignancies, blocks apoptosis induced by chemotherapeutic drugs, including the topoisomerase II inhibitor, etoposide. Etoposide 172-181 BCL2 apoptosis regulator Homo sapiens 4-9 8620501-0 1996 Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Etoposide 47-56 BCL2 apoptosis regulator Homo sapiens 124-129 8752171-3 1996 In agreement with previous studies, Bcl-2 inhibited loss of cell viability (by trypan blue exclusion), the appearance of morphologically apoptotic cells, and the amount of low molecular weight DNA extracted after etoposide exposure (25 microns, 4 h). Etoposide 213-222 BCL2 apoptosis regulator Homo sapiens 36-41 8752171-6 1996 Although Bcl-2 inhibited etoposide-induced apoptosis, it had no effect on the formation of giant, multinucleated cells characteristic of mitotic catastrophe. Etoposide 25-34 BCL2 apoptosis regulator Homo sapiens 9-14 7850782-7 1995 The interaction between androgen and etoposide was mediated through the BCL-2 protein, since bcl-2 antisense oligonucleotides blocked the protective effect of androgens on etoposide cytotoxicity. Etoposide 37-46 BCL2 apoptosis regulator Homo sapiens 72-77 8758442-3 1996 RESULTS: Temporary expression of antisense bcl-2 gene could effectively reduce levels of intrinsic bcl-2 protein of CEM cells and render it more sensitive to etoposide-induced cytotoxicity. Etoposide 158-167 BCL2 apoptosis regulator Homo sapiens 43-48 8758442-4 1996 Moreover, a great deal of apoptotic bodies and ladder DNA was always produced during etoposide-mediated killing of CEM and when CEM expressing bcl-2 antisense RNA served as target cells in particular, the amount of ladder DNA increased to around 40%. Etoposide 85-94 BCL2 apoptosis regulator Homo sapiens 143-148 8758442-5 1996 CONCLUSION: Programmed cell death is one of the mechanisms by which etoposide kills leukemic cells and is modulated by cellular intrinsic bcl-2 protein. Etoposide 68-77 BCL2 apoptosis regulator Homo sapiens 138-143 7850782-7 1995 The interaction between androgen and etoposide was mediated through the BCL-2 protein, since bcl-2 antisense oligonucleotides blocked the protective effect of androgens on etoposide cytotoxicity. Etoposide 37-46 BCL2 apoptosis regulator Homo sapiens 93-98 7850782-7 1995 The interaction between androgen and etoposide was mediated through the BCL-2 protein, since bcl-2 antisense oligonucleotides blocked the protective effect of androgens on etoposide cytotoxicity. Etoposide 172-181 BCL2 apoptosis regulator Homo sapiens 72-77 7850782-7 1995 The interaction between androgen and etoposide was mediated through the BCL-2 protein, since bcl-2 antisense oligonucleotides blocked the protective effect of androgens on etoposide cytotoxicity. Etoposide 172-181 BCL2 apoptosis regulator Homo sapiens 93-98 25607114-5 2015 However, co-treatment with anti-VEGF significantly restored etoposide-induced cell apoptosis and cell cycle arrest, as indicated by the elimination of B-cell lymphoma 2 (Bcl-2), procaspase 3, cyclin B1 and Cdc2. Etoposide 60-69 BCL2 apoptosis regulator Homo sapiens 151-168 30500985-9 2019 CONCLUSIONS AND IMPLICATIONS: The model could accurately predict the effects of anti-tumour drugs that involve the Bcl-2 family pathway, as shown with ABT-199 or etoposide. Etoposide 162-171 BCL2 apoptosis regulator Homo sapiens 115-120 27183435-8 2016 Furthermore, the expression of MRP-1 and Bcl-2 was also inhibited, suggesting that the LRIG1could negatively control MRP-1 and the apoptosis to improve the sensitivity of VP16-related chemotherapy. Etoposide 171-175 BCL2 apoptosis regulator Homo sapiens 41-46 26191229-8 2015 Stable Bcl-2 overexpression led to reduced apoptosis rates as well as Cyt-C and Caspase-3 expressions in Jurkat cells after VP-16 application, which was similar in leucocytes of remission patients. Etoposide 124-129 BCL2 apoptosis regulator Homo sapiens 7-12 8205548-7 1994 Clones expressing high levels of Bcl-2 were resistant to cisplatin- and etoposide-induced cytotoxicity in a dose-dependent manner. Etoposide 72-81 BCL2 apoptosis regulator Homo sapiens 33-38 8395979-0 1993 bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Etoposide 23-32 BCL2 apoptosis regulator Homo sapiens 0-5 8395979-4 1993 In this study, we examined whether bcl-2 overexpression could have effects on etoposide-induced DNA damage and its repair. Etoposide 78-87 BCL2 apoptosis regulator Homo sapiens 35-40 8395979-6 1993 Overexpression of bcl-2 protein inhibited etoposide-induced apoptosis and cytotoxicity. Etoposide 42-51 BCL2 apoptosis regulator Homo sapiens 18-23 8395979-8 1993 These findings indicate that (a) apoptosis or cytotoxicity induced by etoposide can be separated into early events (formation of double-strand breaks, DNA single-strand breaks, and double-strand breaks) and later events (secondary DNA fragmentation or cell death) and (b) bcl-2 inhibits apoptosis and cytotoxicity induced by etoposide at some steps between these events. Etoposide 70-79 BCL2 apoptosis regulator Homo sapiens 272-277 30213983-4 2018 HTLA-ER cells, following etoposide exposure, evaded apoptosis by altering Bax/Bcl2 ratio. Etoposide 25-34 BCL2 apoptosis regulator Homo sapiens 78-82 28587395-8 2017 However, the IC50 for etoposide in sensitive K562 cells was markedly lower than that of K562/ADM cells (50.6+-16.5 and 194+-8.46 microM, respectively), suggesting that the higher expression levels of MDR1 and/or BCL-2 mRNA in resistant cells may be partially responsible for this effect. Etoposide 22-31 BCL2 apoptosis regulator Homo sapiens 212-217 27907860-1 2017 Present study describes the preparation of a polyethylene glycol-grafted oxidized multi-walled carbon nanotubes (oMWCNTs-PEG) hybrid nanosystem as a carrier of etoposide (VP-16) and Bcl-2 phosphorothioate antisense deoxyoligonucleotides (Aso) to achieve a superior cytostastic efficacy in non-small and small cell lung cancer in vitro. Etoposide 160-169 BCL2 apoptosis regulator Homo sapiens 182-187 27419628-5 2016 The results showed that both glutamine deprivation and BPTES pretreatments increased the toxic effects of cisplatin and etoposide on HCC1937 cells, as demonstrated by their reduced proliferation, increased expression of apoptosis-related proteins (cleaved-PARP, cleaved-caspase 9, and cleaved-caspase 3) and decreased Bcl-2/BAX ratio. Etoposide 120-129 BCL2 apoptosis regulator Homo sapiens 318-323 25607114-5 2015 However, co-treatment with anti-VEGF significantly restored etoposide-induced cell apoptosis and cell cycle arrest, as indicated by the elimination of B-cell lymphoma 2 (Bcl-2), procaspase 3, cyclin B1 and Cdc2. Etoposide 60-69 BCL2 apoptosis regulator Homo sapiens 170-175 24559410-7 2014 The BCL2 levels reduced by the hairpin-binding compound led to chemosensitization to etoposide in both in vitro and in vivo models. Etoposide 85-94 BCL2 apoptosis regulator Homo sapiens 4-8 26424010-0 2015 SPATA4 Counteracts Etoposide-Induced Apoptosis via Modulating Bcl-2 Family Proteins in HeLa Cells. Etoposide 19-28 BCL2 apoptosis regulator Homo sapiens 62-67 23435429-2 2014 In this study, we demonstrate that following treatment with the DNA-damaging agents, etoposide or camptothecin, BRCA1 is required for the activation of nuclear factor-kappaB (NF-kappaB), and that BRCA1 and NF-kappaB cooperate to regulate the expression of the NF-kappaB antiapoptotic targets BCL2 and XIAP. Etoposide 85-94 BCL2 apoptosis regulator Homo sapiens 292-296 23161404-8 2013 Moreover, inhibition of GSK3 reduced etoposide-induced association of p53 with Bcl2 and Bax oligomerization. Etoposide 37-46 BCL2 apoptosis regulator Homo sapiens 79-83 22895528-0 2012 Etoposide induces a mixed type of programmed cell death and overcomes the resistance conferred by Bcl-2 in Hep3B hepatoma cells. Etoposide 0-9 BCL2 apoptosis regulator Homo sapiens 98-103 23856142-14 2013 CONCLUSION: Targeting to inhibit antiapoptotic mitochondrial gene Bcl-2 expression in A549 cells specifically decreased the mRNA of ERCC1, TYMS, and TOP2alpha genes, and significantly increased the sensitivities of A549 cells to chemotherapeutic agents such as etoposide, cisplatin, paclitaxel and navelbine. Etoposide 261-270 BCL2 apoptosis regulator Homo sapiens 66-71 23610963-0 2013 Cytotoxicity of etoposide in cancer cell lines in vitro after BCL-2 and C-RAF gene silencing with antisense oligonucleotides. Etoposide 16-25 BCL2 apoptosis regulator Homo sapiens 62-67 22895528-5 2012 Furthermore, this study was conducted to examine whether etoposide overcomes the resistance conferred by Bcl-2 in Hep3B hepatoma cells. Etoposide 57-66 BCL2 apoptosis regulator Homo sapiens 105-110 22895528-10 2012 Importantly, etoposide can effectively induce cell death in Bcl-2-overexpressing Hep3B cells. Etoposide 13-22 BCL2 apoptosis regulator Homo sapiens 60-65 22895528-14 2012 To this end, we observed that etoposide-induced mixed type of programmed cell death is associated with the dissociation of Bcl-2 from Beclin-1. Etoposide 30-39 BCL2 apoptosis regulator Homo sapiens 123-128 22895528-15 2012 Taken together, etoposide induces a mixed type of programmed cell death and overcomes the resistance conferred by Bcl-2 in Hep3B hepatoma cells. Etoposide 16-25 BCL2 apoptosis regulator Homo sapiens 114-119 22491967-5 2012 Second, we have highlighted that during etoposide or TNF-alpha treatments, intracellular ROS level, MMP and cell death are all regulated by caspases and Bcl-2, with caspases acting early in the process. Etoposide 40-49 BCL2 apoptosis regulator Homo sapiens 153-158 22238053-0 2012 Quantitative expression analysis of the apoptosis-related genes BCL2, BAX and BCL2L12 in gastric adenocarcinoma cells following treatment with the anticancer drugs cisplatin, etoposide and taxol. Etoposide 175-184 BCL2 apoptosis regulator Homo sapiens 64-68 22238053-11 2012 Treatment of AGS cells with 10 muM cisplatin, 0.5 muM etoposide and 10 nM taxol affected the BCL2, BAX and BCL2L12 mRNA levels, compared to the untreated cells. Etoposide 54-63 BCL2 apoptosis regulator Homo sapiens 93-97 22238053-12 2012 Cisplatin and etoposide induced a major down-regulation in the BCL2 mRNA levels after 72 h of treatment, while the BAX mRNA levels were slightly up-regulated. Etoposide 14-23 BCL2 apoptosis regulator Homo sapiens 63-67 22275372-10 2012 Furthermore, the specific knockdown of Bcl-2 in Nrf2-activated tumor cells led to increased etoposide-induced apoptosis and decreased cell survival and growth/proliferation. Etoposide 92-101 BCL2 apoptosis regulator Homo sapiens 39-44